214 related articles for article (PubMed ID: 25870918)
1. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.
Horowitz NS; Wright AA
Gynecol Oncol; 2015 Jul; 138(1):201-6. PubMed ID: 25870918
[TBL] [Abstract][Full Text] [Related]
2. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
3. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
Griggs JJ; Mangu PB; Anderson H; Balaban EP; Dignam JJ; Hryniuk WM; Morrison VA; Pini TM; Runowicz CD; Rosner GL; Shayne M; Sparreboom A; Sucheston LE; Lyman GH;
J Clin Oncol; 2012 May; 30(13):1553-61. PubMed ID: 22473167
[TBL] [Abstract][Full Text] [Related]
4. The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients.
Hansen J; Stephan JM; Freesmeier M; Bender D; Button A; Goodheart MJ
Gynecol Oncol; 2015 Jul; 138(1):154-8. PubMed ID: 25958318
[TBL] [Abstract][Full Text] [Related]
5. Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients.
Miyahara T; Mochinaga S; Kimura S; Aragane N; Yakabe T; Morita S; Okudaira K; Fujito H
Cancer Chemother Pharmacol; 2013 Jan; 71(1):175-82. PubMed ID: 23064956
[TBL] [Abstract][Full Text] [Related]
6. Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
Hall RG; Jean GW; Sigler M; Shah S
Ann Pharmacother; 2013 Dec; 47(12):1666-74. PubMed ID: 24259627
[TBL] [Abstract][Full Text] [Related]
7. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).
Hunter RJ; Navo MA; Thaker PH; Bodurka DC; Wolf JK; Smith JA
Cancer Treat Rev; 2009 Feb; 35(1):69-78. PubMed ID: 18922643
[TBL] [Abstract][Full Text] [Related]
8. The impact of obesity on the incidence and treatment of gynecologic cancers: a review.
Modesitt SC; van Nagell JR
Obstet Gynecol Surv; 2005 Oct; 60(10):683-92. PubMed ID: 16186785
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
[TBL] [Abstract][Full Text] [Related]
11. Obesity and chemotherapy administration: between empiric and mathematic method review.
Bouleftour W; Mery B; Chanal E; Rowinski E; Viard A; Forges F; Fournel P; Rivoirard R
Acta Oncol; 2019 Jun; 58(6):880-887. PubMed ID: 30907190
[No Abstract] [Full Text] [Related]
12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
13. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
[TBL] [Abstract][Full Text] [Related]
14. Obesity and gynecologic cancer etiology and survival.
Webb PM
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714508
[TBL] [Abstract][Full Text] [Related]
15. Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes.
Doll KM; Kalinowski AK; Snavely AC; Irwin DE; Bensen JT; Bae-Jump VL; Kim KH; Van Le L; Clarke-Pearson DL; Gehrig PA
Cancer; 2015 Feb; 121(3):395-402. PubMed ID: 25250951
[TBL] [Abstract][Full Text] [Related]
16. Obesity and female malignancies.
Benedetto C; Salvagno F; Canuto EM; Gennarelli G
Best Pract Res Clin Obstet Gynaecol; 2015 May; 29(4):528-40. PubMed ID: 25779915
[TBL] [Abstract][Full Text] [Related]
17. Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.
Purcell SA; Elliott SA; Kroenke CH; Sawyer MB; Prado CM
Curr Oncol Rep; 2016 Feb; 18(2):8. PubMed ID: 26769113
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
19. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Meyerhardt JA; Tepper JE; Niedzwiecki D; Hollis DR; McCollum AD; Brady D; O'Connell MJ; Mayer RJ; Cummings B; Willett C; Macdonald JS; Benson AB; Fuchs CS
J Clin Oncol; 2004 Feb; 22(4):648-57. PubMed ID: 14966087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
